PMV Pharmaceuticals (PMVP)
(Delayed Data from NSDQ)
$1.52 USD
+0.04 (2.70%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.51 -0.01 (-0.66%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PMVP 1.52 +0.04(2.70%)
Will PMVP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PMVP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PMVP
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing
PMVP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PMVP
PMV Pharmaceuticals Holds 2025 Annual Stockholder Meeting
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences | PMVP Stock News
TD Cowen Keeps Their Buy Rating on PMV Pharmaceuticals (PMVP)
PMV Pharmaceuticals Reports Q1 2025 Financial Results
PMV Pharmaceuticals GAAP EPS of -$0.34 beats by $0.03